Media Articles Related to Oxsoralen-Ultra (Methoxsalen)
New Drug on the Block: Apremilast for Plaque Psoriasis
Source: Medscape Dermatology Headlines [2015.02.27]
Will this new oral agent for plaque psoriasis provide the relief your patients need?
Source: MedicineNet Actinic Keratosis Specialty [2015.01.28]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/28/2015 12:00:00 AM
Proteins identified that are likely to trigger psoriasis
Source: Arthritis / Rheumatology News From Medical News Today [2015.01.25]
Case Western Reserve scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world.
New Psoriasis Drug Approved
Source: MedicineNet Psoriasis Specialty [2015.01.22]
Title: New Psoriasis Drug Approved
Category: Health News
Created: 1/21/2015 12:00:00 AM
Last Editorial Review: 1/22/2015 12:00:00 AM
Psoriasis: Otezla (apremilast), receives European marketing authorisation in two therapeutic indications
Source: Arthritis / Rheumatology News From Medical News Today [2015.01.21]
Celgene UK has announced that the European Commission has licensed Otezla, the Company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications:[ii]For the...
Published Studies Related to Oxsoralen-Ultra (Methoxsalen)
Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. [2006.10]
BACKGROUND: Bath-psoralen plus ultraviolet A (PUVA) radiation therapy is increasingly replacing oral PUVA because of its superior short- and long-term safety profile. Several investigations in recent years have led to a refinement of the bath-PUVA protocol; however, the optimal therapeutic concentration of methoxsalen in the bath water has as yet not been delineated. OBJECTIVES: The therapeutic efficacy and tolerability of bath-PUVA by using two different dilutions of methoxsalen (1 mg/L vs 5 mg/L or 0.0001% vs 0.0005%) were compared in 46 patients with chronic plaque-type psoriasis in a prospective, randomized, double-blind study... CONCLUSIONS: Our data indicate that in bath-PUVA treatment the use of a high (5 mg/L) methoxsalen concentration is substantially more effective in clearing chronic plaque-type psoriasis than a low (1 mg/L) concentration.
Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. [2000.01]
Methoxsalen (8-methoxypsoralen) is an effective and selective mechanism-based inhibitor of human hepatic cytochrome P-450 (CYP)2A6 in vitro, and may have utility as a clinical probe for CYP2A6-catalyzed xenobiotic metabolism in humans in vivo...
Comparison of minimal phototoxic dose and skin type for determining initial UVA dose in oral liquid methoxsalen photochemotherapy for the treatment of psoriasis. [1991.12]
Twenty-five patients with extensive psoriasis were randomly assigned into one of three groups, each receiving 0.5 mg/kg of oral liquid methoxsalen photochemotherapy followed 1 h later by exposure to long-wave ultraviolet light (UVA). The sole difference between the three groups was the method used to determine the initial UVA dose, which was either based on skin type, 25% of the minimal phototoxic dose (MPD), or 50% of the MPD...
Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. [2006.07]
Furanocoumarins increase the bioavailability of drugs that are CYP3A4 substrates. A possible interaction of methoxsalen with cyclosporine was evaluated in 12 healthy volunteers following oral administration of 40 mg methoxsalen, 200 mg cyclosporine, or a combination of both in a randomized crossover study...
The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. [2003.12]
Nicotine is metabolized to the inactive metabolite cotinine by cytochrome P450 2A6. NNK, or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is a potent procarcinogen shown to be activated to a reactive mutagenic metabolite by the enzyme CYP2A6...
Clinical Trials Related to Oxsoralen-Ultra (Methoxsalen)
A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease [Recruiting]
The purpose of this study is to evaluate the safety and effectiveness of extracorporeal
photopheresis therapy when added to standard drug therapies administered to patients with
moderate to severe chronic graft-versus-host disease.
Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis [Recruiting]
The purpose of this prospective, randomized, controlled, single-blinded investigation is to
study the efficacy, tolerability and safety of oral photochemotherapy (PUVA) combined with
acitretin versus oral PUVA combined with systemic fumaric acid esters (FAE) in patients with
pustular palmoplantar psoriasis.
Patients will be randomized and allocated in concealed manner to one of the two treatment
arms: acitretin-PUVA or FAE-PUVA.
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART) [Recruiting]
The objectives of this clinical trial are to:
- Assess the safety of using extracorporeal photoimmune therapy with the photosensitizing
agent Uvadex in the treatment of HIV-1 infection;
- Evaluate the effects of this therapy on HIV-1 viral load by polymerase chain reaction
- Evaluate the effects of this therapy on CD4+, CD8+ cells and CD4/CD8 ratio;
- Evaluate the effects of this therapy on the patient's immune system, by skin reactivity
to a standard anergy panel.
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-Versus-Host Disease [Active, not recruiting]
The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX
(ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the
prevention of Graft-versus-Host Disease (GvHD).
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease [Active, not recruiting]
his study will explore the safety and activity of ECP treatment with UVADEX in inducing a
clinical response (i. e., a CDAI decrease greater than or equal to 100 from baseline and/or a
CDAI < 150) over a 12-week period in moderately active Crohn’s disease (CDAI greater than or
equal to 220 to < 450) patients who are refractory or intolerant to immunosuppressants and/or
anti-TNF agents. This study will also assess response to continued treatment during a
12-week Extension Period in patients who have a clinical response at Week 12 of the Treatment
Period and elect to participate in the Extension Period.